Cargando…

Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection

It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts. We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 con...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sehoon, Yang, Seung-Hee, Kim, Jiyeon, Cho, Semin, Yang, Jaeseok, Min, Sang-Il, Ha, Jongwon, Jeong, Chang Wook, Bhoo, Seong Hee, Kim, Yong Chul, Kim, Dong Ki, Oh, Kook-Hwan, Joo, Kwon Wook, Kim, Yon Su, Moon, Kyung Chul, Song, Eun Young, Lee, Hajeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131656/
https://www.ncbi.nlm.nih.gov/pubmed/35634584
http://dx.doi.org/10.3389/ti.2022.10099
_version_ 1784713218951741440
author Park, Sehoon
Yang, Seung-Hee
Kim, Jiyeon
Cho, Semin
Yang, Jaeseok
Min, Sang-Il
Ha, Jongwon
Jeong, Chang Wook
Bhoo, Seong Hee
Kim, Yong Chul
Kim, Dong Ki
Oh, Kook-Hwan
Joo, Kwon Wook
Kim, Yon Su
Moon, Kyung Chul
Song, Eun Young
Lee, Hajeong
author_facet Park, Sehoon
Yang, Seung-Hee
Kim, Jiyeon
Cho, Semin
Yang, Jaeseok
Min, Sang-Il
Ha, Jongwon
Jeong, Chang Wook
Bhoo, Seong Hee
Kim, Yong Chul
Kim, Dong Ki
Oh, Kook-Hwan
Joo, Kwon Wook
Kim, Yon Su
Moon, Kyung Chul
Song, Eun Young
Lee, Hajeong
author_sort Park, Sehoon
collection PubMed
description It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts. We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 control subjects without rejection, and determined the titers of 39 non-HLA antibodies including antibodies for angiotensin II receptor type I and MICA. We compared all these non-HLA antibody titers among the study groups. Then, we investigated their association with the risk of death-censored graft failure in ABMR cases. Among the antibodies evaluated, anti-collagen type I (p = 0.001) and type III (p < 0.001) antibody titers were significantly higher in ABMR cases than in both TCMR cases and no-rejection controls. Both anti-collagen type I [per 1 standard deviation (SD), adjusted odds ratio (OR), 11.72 (2.73–76.30)] and type III [per 1 SD, adjusted OR, 6.22 (1.91–31.75)] antibodies were significantly associated with the presence of ABMR. Among ABMR cases, a higher level of anti-collagen type I [per 1 SD, adjusted hazard ratio (HR), 1.90 (1.32–2.75)] or type III per 1 SD, [adjusted HR, 1.57 (1.15–2.16)] antibody was associated with a higher risk of death-censored graft failure. In conclusion, post-transplant anti-collagen type I and type III antibodies may be novel non-HLA antibodies related to ABMR of kidney allografts.
format Online
Article
Text
id pubmed-9131656
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91316562022-05-26 Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection Park, Sehoon Yang, Seung-Hee Kim, Jiyeon Cho, Semin Yang, Jaeseok Min, Sang-Il Ha, Jongwon Jeong, Chang Wook Bhoo, Seong Hee Kim, Yong Chul Kim, Dong Ki Oh, Kook-Hwan Joo, Kwon Wook Kim, Yon Su Moon, Kyung Chul Song, Eun Young Lee, Hajeong Transpl Int Health Archive It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts. We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 control subjects without rejection, and determined the titers of 39 non-HLA antibodies including antibodies for angiotensin II receptor type I and MICA. We compared all these non-HLA antibody titers among the study groups. Then, we investigated their association with the risk of death-censored graft failure in ABMR cases. Among the antibodies evaluated, anti-collagen type I (p = 0.001) and type III (p < 0.001) antibody titers were significantly higher in ABMR cases than in both TCMR cases and no-rejection controls. Both anti-collagen type I [per 1 standard deviation (SD), adjusted odds ratio (OR), 11.72 (2.73–76.30)] and type III [per 1 SD, adjusted OR, 6.22 (1.91–31.75)] antibodies were significantly associated with the presence of ABMR. Among ABMR cases, a higher level of anti-collagen type I [per 1 SD, adjusted hazard ratio (HR), 1.90 (1.32–2.75)] or type III per 1 SD, [adjusted HR, 1.57 (1.15–2.16)] antibody was associated with a higher risk of death-censored graft failure. In conclusion, post-transplant anti-collagen type I and type III antibodies may be novel non-HLA antibodies related to ABMR of kidney allografts. Frontiers Media S.A. 2022-05-11 /pmc/articles/PMC9131656/ /pubmed/35634584 http://dx.doi.org/10.3389/ti.2022.10099 Text en Copyright © 2022 Park, Yang, Kim, Cho, Yang, Min, Ha, Jeong, Bhoo, Kim, Kim, Oh, Joo, Kim, Moon, Song and Lee. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Park, Sehoon
Yang, Seung-Hee
Kim, Jiyeon
Cho, Semin
Yang, Jaeseok
Min, Sang-Il
Ha, Jongwon
Jeong, Chang Wook
Bhoo, Seong Hee
Kim, Yong Chul
Kim, Dong Ki
Oh, Kook-Hwan
Joo, Kwon Wook
Kim, Yon Su
Moon, Kyung Chul
Song, Eun Young
Lee, Hajeong
Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
title Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
title_full Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
title_fullStr Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
title_full_unstemmed Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
title_short Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
title_sort clinical significances of anti-collagen type i and type iii antibodies in antibody-mediated rejection
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131656/
https://www.ncbi.nlm.nih.gov/pubmed/35634584
http://dx.doi.org/10.3389/ti.2022.10099
work_keys_str_mv AT parksehoon clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT yangseunghee clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT kimjiyeon clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT chosemin clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT yangjaeseok clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT minsangil clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT hajongwon clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT jeongchangwook clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT bhooseonghee clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT kimyongchul clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT kimdongki clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT ohkookhwan clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT jookwonwook clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT kimyonsu clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT moonkyungchul clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT songeunyoung clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection
AT leehajeong clinicalsignificancesofanticollagentypeiandtypeiiiantibodiesinantibodymediatedrejection